华海药业：获得马来酸曲美布汀片《药品注册证书》

Core Viewpoint - Huahai Pharmaceutical has received approval from the National Medical Products Administration for the drug Trimebutine Maleate Tablets, which is expected to generate approximately 340 million yuan in domestic market sales by 2025 [1] Group 1: Product Approval - The drug Trimebutine Maleate Tablets has been granted a drug registration certificate with approval number H20263372 [1] - This medication is intended to improve gastrointestinal motility disorders and symptoms of irritable bowel syndrome [1] Group 2: Financial Investment - The company has invested approximately 10.1 million yuan in the research and development of this drug [1] Group 3: Market Impact - The approved product is considered to have passed the consistency evaluation, which will enrich the product line and enhance competitiveness [1] - However, production and sales may be influenced by policies and market factors [1]